J+J Professional Inc

Vertex Pharmaceuticals Incorporated is a global biotechnology company engaged in the discovery and development of breakthrough small molecule drugs for serious diseases. The company commercializes its products independently and in collaboration with major pharmaceutical companies. Vertex s product line includes drugs for viral diseases, inflammation, autoimmune diseases and cancer. Vertex is developing treatments for cancer, HIV and AIDS and pain through collaborations with some of the leading pharmaceutical companies. The company has collaborations with Cystic Fibrosis Foundation Therapeutics, GlaxoSmithKline, Kissei Pharmaceutical, Merck & Co., Mitsubishi Pharma Corporation and Novartis Pharma. Vertex co-promotes the HIV and AIDS protease inhibitor, Lexiva, with GlaxoSmithKline. Vertex Pharmaceuticals Incorporated is located in Cambridge, Mass.

Cell Signaling Technologies, based in Beverly, MA, is recognized globally for its extensive range of high-quality antibodies and related research products, serving the life sciences community for over 25 years. The company's product offerings include primary and secondary antibodies, ELISA kits, cellular assay kits, and an array of reagents and comprehensive solutions tailored for various applications including cancer research, immunology, and neuroscience. With a commitment to reliability and validation, Cell Signaling Technologies provides leading-edge solutions for research through robust assay platforms and continuous supply of essential products. Their dedication to environmental and social responsibility further underscores their role as a trusted partner in advancing scientific discovery. Generated from the website

Matrivax Research & Development Corporation, based in Boston, MA, is at the forefront of vaccine innovation, dedicated to developing life-saving vaccines for populations in need worldwide. Their efforts focus on a next-generation pneumococcal vaccine and a novel C. difficile vaccine, both addressing critical global health threats. The pneumococcal vaccine aims to significantly reduce the impact of Streptococcus pneumoniae infections, which claim over one million lives annually. Meanwhile, the C. difficile vaccine targets the bacteria and toxins responsible for a substantial number of infections in the U.S., presenting a promising solution to an urgent public health crisis. Generated from the website